Vertex's kidney disease drug meets main goal in late-stage trial
09/03/2026 20:08
March 9 (Reuters) - Vertex Pharmaceuticals VRTX.O said on Monday that its experimental kidney disease drug met the main goal of a late-stage trial. (Reporting by Kamal Choudhury in Bengaluru; Editing by Sahal Muhammed) ((Kamal.Choudhury@thomsonreuters.com;))
Recent news on Vertex Pharmaceuticals
See all newsBrief: Vertex Announces US FDA Acceptance Of Biologics License Application For Accelerated Approval Of Povetacicept In IgA Nephropathy
U.S. RESEARCH ROUNDUP- CAVA Group, Eagle Materials, Vertiv Holdings
Vertex Q1 adjusted EPS beats estimates, revenue rises 8%
Vertex tops profit estimates as sales of new cystic fibrosis drug surge
Brief: Vertex Pharmaceuticals Q1 Adjusted EPS USD 4.47 Vs. IBES Estimate USD 4.31